As previously reported, Craig-Hallum initiated coverage of Biote (BTMD) with a Buy rating and $12 price target Consumer interest in next-gen therapies like hormone replacement therapy, or HRT ...

“Biote’s third quarter revenue increased 12.8% from the prior-quarter period, driven by continued growth in procedure revenue and a strong return to growth in our dietary supplements ...

He is the founder of the Institute for Hormonal Balance, a clinic specializing in hormone replacement therapies, and BioTE Medical, the largest provider of hormone implants in the United States and a ...

Biote Corp. (BTMD) came out with quarterly earnings of $0.33 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to loss of $0.11 per share a year ago. These figures ...

In a report released on December 20, Alex Fuhrman from Craig-Hallum maintained a Buy rating on biote (BTMD – Research Report), with a price target of $0.00. The company’s shares closed last ...

IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness ...